Search
Insulin lispro
go.drugbank.com/drugs/DB00046ApprovedInvestigationalInsulin lispro is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. … Insulin is also used in the treatment of Type 2 Diabetes (T2D), another form of diabetes mellitus that is a slowly progressing metabolic disorder caused by a combination of genetic and lifestyle factors
Products: HUMALOG 100 U/ML, HUMALOG KWIKPEN®200 U / MLLutein
go.drugbank.com/drugs/DB00137ApprovedNutraceuticalIn green plants, xanthophylls act to modulate light energy and serve as non-photochemical quenching agents to deal with triplet chlorophyll (an excited form of chlorophyll), which is overproduced at very … Lutein is synthesized only by plants and like other xanthophylls is found in high quantities in green leafy vegetables such as spinach, kale and yellow carrots.
Stiripentol
go.drugbank.com/drugs/DB09118ApprovedInvestigational[A19739] Approved in the US, Canada, and Europe, stiripentol is used to treat seizures associated with Dravet syndrome.[L880,L42500,L42510] It is marketed under the brand name Diacomit.
Carbamazepine
go.drugbank.com/drugs/DB00564ApprovedInvestigationalIt was initially approved by the FDA in 1965.[A180301] Aside from the above uses, this drug is also given to control the symptoms of bipolar 1.
Dupilumab
go.drugbank.com/drugs/DB12159ApprovedInvestigationalIt was first approved by the FDA in 2017. … [A180478] Dupilumab was generated by recombinant DNA technology in Chinese Hamster Ovary cell suspension culture.
Rabeprazole
go.drugbank.com/drugs/DB01129ApprovedInvestigationalIt is a prodrug - in the acid environment of the parietal cells it turns into active sulphenamide form. … Rabeprazole inhibits the H+, K+ATPase of the coating gastric cells and dose-dependent oppresses basal and stimulated gastric acid secretion.
Ibrutinib
go.drugbank.com/drugs/DB09053ApprovedInvestigationalApril 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. … [L45894] Ibrutinib was approved by the EMA in October 2014 [L45884] and by Health Canada in November 2014.
Antihemophilic factor human
go.drugbank.com/drugs/DB13192ApprovedInvestigationalFactor VIII, but does not contain the B-domain, which has no known biological function and [DB11607], which is a fully recombinant factor VIII-Fc fusion protein which has an extended half-life compared … The complex was developed by CSL Behring or Baxter Healthcare Corporation and approved in the 90s.
Mixtures: VONCENTO 1000 UI/ 2400 UIIcotrokinra
go.drugbank.com/drugs/DB21724ApprovedInvestigational[L56108,L56118] Icotrokinra was approved by the US FDA in March 2026 for the systemic treatment of moderate-to-severe plaque psoriasis.[L56108] … It was jointly discovered and developed by Protagonist and Johnson & Johnson[L56118] and provides a novel, oral treatment option for patients requiring systemic therapy for plaque psoriasis.
Tranexamic acid
go.drugbank.com/drugs/DB00302ApprovedInvestigationalIt possesses a similar mechanism of action to [aminocaproic acid] but is approximately 10-fold more potent. … [L31883] It was first patented in 1957[A230108] and received its initial US approval in 1986.[L31858]